Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9

Author(s):
Tuin, S.J.L. van der; Kuhnast, S.; Berbee, J.F.P.; Verschuren, L.; Pieterman, E.J.; Havekes, L.M.; Hoorn, J.W.A. van der; Rensen, P.C.N. (0000-0002-8455-4988); Jukema, J.W. (0000-0002-3246-8359); Princen, H.M.G.; Dijk, K.W. van; Wang, Y.N.
Published
2015
Publication type
Article / Letter to editor
cholesteryl ester transfer proteincholesterolmetabolismdrug therapyhypolipidemic drugslow density lipoproteinlipidslipoproteinsproprotein convertase subtilisinkexin type 9very low density lipoprotein
Date issued
2015-11-30
Language
English
Is part of
Journal of Lipid Research (2015), Vol. 56, no. 11, p. 2085-2093
hdl
1887/101299
doi
10.1194/jlr.M057794